Genmab A/S (GMAB) Reports 45.9% ORR, 9.5m PFS for Rina-S in Platinum-Resistant Ovarian Cancer
Genmab reported Part C Phase 1/2 RAINFOL-01 results for Rina-S in platinum-resistant ovarian cancer: confirmed ORR 45.9% (5 CRs), mDOR 12.1m, and mPFS 9.5m among 109 patients, with activity regardless of FRα expression and prior mirvetuximab.Material DetailsContext by AI AnalystThis is mid-stage ef…